Literature DB >> 18949016

Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy.

C Tosch1, M Geist, C Ledoux, C Ziller-Remi, S Paul, P Erbs, N Corvaia, P Von Hoegen, J-M Balloul, H Haegel.   

Abstract

The delivery of stimulatory signals to dendritic cells (DCs) in the tumor microenvironment could be an effective means to break tumor-induced tolerance. The work presented here evaluates the immunostimulatory properties of pathogen-associated molecular patterns (PAMPs), microbial molecules which bind Toll-like receptors and deliver activating signals to immune cells, when expressed in tumor cells using adenoviral (Ad) vectors. In vitro, transduction of A549 tumor cells with Ad vectors expressing either flagellin from Listeria monocytogenes or P40 protein from Klebsiella pneumoniae induced the maturation of human monocyte-derived DCs in co-cultures. In mixed lymphocyte reactions (MLRs), Ad-flagellin and Ad-P40 transduction of tumor cells stimulated lymphocyte proliferation and the secretion of IFN-gamma. In vivo, these vectors were used either as stand-alone immunoadjuvants injected intratumorally or as vaccine adjuvants combined with a tumor antigen-expressing vector. When Ad-PAMPs were administered intratumorally to mice bearing subcutaneous syngeneic B16F0-CAR (cocksackie-adenovirus receptor) melanomas, tumor progression was transiently inhibited by Ad-P40. In a therapeutic vaccine setting, the combination of Ad-MUC1 and Ad-PAMP vectors injected subcutaneously delayed the growth of implanted RenCa-MUC1 tumors and improved tumor rejection when compared with vaccination with Ad-MUC1 alone. These results suggest that Ad-PAMPs could be effective immunoadjuvants for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18949016     DOI: 10.1038/cgt.2008.85

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  6 in total

1.  A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells.

Authors:  Xiao-Tong Song; Meghan E Turnis; Xiaoou Zhou; Wei Zhu; Bang-Xing Hong; Lisa Rollins; Brian Rabinovich; Si-Yi Chen; Cliona M Rooney; Stephen Gottschalk
Journal:  Mol Ther       Date:  2010-10-19       Impact factor: 11.454

2.  Flagellin in fusion with human rotavirus structural proteins exerts an adjuvant effect when delivered with replicating but non-disseminating adenovectors through the intrarectal route.

Authors:  Aurélie Girard; Elodie Roques; Bernard Massie; Denis Archambault
Journal:  Mol Biotechnol       Date:  2014-05       Impact factor: 2.695

Review 3.  Tumor microbiome metabolism: A game changer in cancer development and therapy.

Authors:  Xiaozhuang Zhou; Shruthi Kandalai; Farzana Hossain; Qingfei Zheng
Journal:  Front Oncol       Date:  2022-07-25       Impact factor: 5.738

4.  The use of adenoviral vectors in gene therapy and vaccine approaches.

Authors:  Natália Meneses Araújo; Ileana Gabriela Sanchez Rubio; Nicholas Pietro Agulha Toneto; Mirian Galliote Morale; Rodrigo Esaki Tamura
Journal:  Genet Mol Biol       Date:  2022-10-07       Impact factor: 2.087

5.  The adjuvant activity of alphavirus replicons is enhanced by incorporating the microbial molecule flagellin into the replicon.

Authors:  Maria L Knudsen; Daniel X Johansson; Linda Kostic; Eva K L Nordström; Karin Tegerstedt; Anna Pasetto; Steven E Applequist; Karl Ljungberg; Jean-Claude Sirard; Peter Liljeström
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

6.  Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.

Authors:  V Mett; E A Komarova; K Greene; I Bespalov; C Brackett; B Gillard; A S Gleiberman; I A Toshkov; S Aygün-Sunar; C Johnson; E Karasik; M Bapardekar-Nair; O V Kurnasov; A L Osterman; P S Stanhope-Baker; C Morrison; M T Moser; B A Foster; A V Gudkov
Journal:  Oncogene       Date:  2017-10-02       Impact factor: 9.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.